The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | The current and future role of bispecifics in R/R DLBCL: epcoritamab, glofitamab & more
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the role of bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), highlighting the recent approval of epcoritamab and glofitamab. Dr Westin comments on the suitability of bispecifics as a third-line treatment option in this disease setting, and talks on areas for further study. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
